Christos Kouimtsidis

Dr. Christos Kouimtsidis

Brain Sciences, medical school, Imperial College London, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2020 in Basic and Clinical Neuroscience Journal
Verified
Journal Article
Open access
PDF file
AFAli Farhoudian
Ali Farhoudian
ABAlexander Baldacchino
Alexander Baldacchino
NCNicolas Clark
Nicolas Clark
GGGilberto Gerra
Gilberto Gerra
HEHamed Ekhtiari
Hamed Ekhtiari
EREmran Mohammad Razaghi
Emran Mohammad Razaghi
Coronavirus disease 2019 (COVID-19) is escalating all over the world and has higher morbidities and mortalities in certain vulnerable populations. People who use drugs (PWUD) are a marginalized and stigmatized group with weaker immunity responses, vulnerability to stress, poor health conditions, high-risk behaviors, and lower access to health care services. These ...

29 April 2021 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
SRSeyed Ramin Radfar
Seyed Ramin Radfar
CJCornelis A. J. De Jong
Cornelis A. J. De Jong
AFAli Farhoudian
Ali Farhoudian
MEMohsen Ebrahimi
Mohsen Ebrahimi
PRParnian Rafei
Parnian Rafei
ICISAM-PPIG Global Survey Consortium
ISAM-PPIG Global Survey Consortium
Background:The coronavirus disease 2019 (COVID-19) pandemic has impacted people with substance use disorders (SUDs) worldwide, and healthcare systems have reorganized their services in response to the pandemic.Methods:One week after the announcement of the COVID-19 as a pandemic, in a global survey, 177 addiction medicine professionals described COVID-19-related health responses in their own 77 countries in terms of SUD treatment and harm reduction services. The health responses were categorized around (1) managerial measures and systems, (2) logistics, (3) service providers, and (4) vulnerable groups.Results:Respondents from over 88% of countries reported that core medical and psychiatric care for SUDs had continued; however, only 56% of countries reported having had any business continuity plan, and 37.5% of countries reported shortages of methadone or buprenorphine supplies. Participants of 41% of countries reported partial discontinuation of harm-reduction services such as needle and syringe programs and condom distribution. Fifty-seven percent of overdose prevention interventions and 81% of outreach services were also negatively impacted.Conclusions:Participants reported that SUD treatment and harm-reduction services had been significantly impacted globally early during the COVID-19 pandemic. Based on our findings, we highlight several issues and complications resulting from the pandemic concerning people with SUDs that should be tackled more efficiently during the future waves or similar pandemics. The issues and potential strategies comprise the following: (1) helping policymakers to generate business continuity plans, (2) maintaining the use of evidence-based interventions for people with SUDs, (3) being prepared for adequate medication supplies, (4) integrating harm reduction programs with other treatment modalities, and (5) having specific considerations for vulnerable groups such as immigrants and refugees.

4 March 2003 in Addictive Behaviors
Verified
Journal Article
Closed access
Christos KouimtsidisChristos Kouimtsidis
Christos Kouimtsidis
MRMartina Reynolds
Martina Reynolds
MHMary Hunt
Mary Hunt
JLJackie Lind
Jackie Lind
JBJonathan Beckett
Jonathan Beckett
HGHamid Ghodse
Hamid Ghodse

12 May 2017 in Trials
Verified
Journal Article
Open access
PDF file
Christos KouimtsidisChristos Kouimtsidis
Christos Kouimtsidis
ABAlessandro Bosco
Alessandro Bosco
KSKatrina Scior
Katrina Scior
GBGianluca Baio
Gianluca Baio
Rachael HunterRachael Hunter
Rachael Hunter
AHAngela Hassiotis
Angela Hassiotis
Extended brief interventions (EBIs) are effective in targeting alcohol misuse in the general population. However, little is known of the effects of EBI in adults with intellectual (also known as learning) disabilities. In this feasibility trial we compared EBI with usual care for alcohol misuse in adults with mild to moderate Intellectual Disability (ID). The study took place in three community ID networks of services in England. Participants aged 18–65 years with reported alcohol problems, a score ≥8 on the Alcohol Use Disorder Identification Test (AUDIT), and IQ <70 (+/5%CI) were recruited and were randomly allocated to either EBI (five weekly sessions and one follow-up at 8 weeks) and usual care or usual care alone. Research assistants were blind to arm allocation. Research assessments took place at baseline, 2 and 3 months. The primary outcome was reduction in alcohol consumption measured by the AUDIT. Preliminary health economic analysis was performed to investigate the costs of delivering EBI and the feasibility of a cost-effectiveness analysis in a full trial. The trial is closed. Participants were recruited from January 2014 to August 2015. Thirty individuals were randomised (15 in each arm) and provided primary outcome data. In regard to harmful drinking, at baseline, all the participants exceeded the relevant threshold. At 8 weeks, the proportion of participants with harmful drinking had decreased to 60% for both groups, and at 12 weeks it had decreased by 66°7% and 46°7% for the intervention and the control groups, respectively. The unit cost for the delivery of EBI is £430. Recruitment to this trial has been proven challenging as prevalence of alcohol misuse in the targeted population was lower than anticipated. EBI may provide an effective low-intensity treatment for this population. Participants’ and carers’ feedback on their experience was overall positive. Further work needs to be undertaken to ascertain the group of participants that should be participating in a future definitive trial. Psychological Intervention Alcohol Misuse Learning Disability; isrctn.com, identifier: ISRCTN58783633 . Registered on 17 December 2013.

18 February 2021 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
Christos KouimtsidisChristos Kouimtsidis
Christos Kouimtsidis
BPBernadette Pauly
Bernadette Pauly
Tessa ParkesTessa Parkes
Tessa Parkes
TSTim Stockwell
Tim Stockwell
ABAlexander Mario Baldacchino
Alexander Mario Baldacchino
The COVID-19 pandemic is presenting significant challenges for health and social care systems globally. The implementation of unprecedented public health measures, alongside the augmentation of the treatment capacity for those severely affected by COVID-19, are compromising and limiting the delivery of essential care to people with severe substance use problems and, in some cases, widening extreme social inequities such as poverty and homelessness. This global pandemic is severely challenging current working practices. However, these challenges can provide a unique opportunity for a flexible and innovative learning approach, bringing certain interventions into the spotlight. Harm reduction responses are well-established evidenced approaches in the management of opioid dependence but not so well-known or implemented in relation to alcohol use disorders. In this position paper, we explore the potential for expanding harm reduction approaches during the COVID-19 crisis and beyond as part of substance use treatment services. We will examine alcohol use and related vulnerabilities during COVID-19, the impact of COVID-19 on substance use services, and the potential philosophical shift in orientation to harm reduction and outline a range of alcohol harm reduction approaches. We discuss relevant aspects of the Structured Preparation for Alcohol Detoxification (SPADe) treatment model, and Managed Alcohol Programs (MAPs), as part of a continuum of harm reduction and abstinence orientated treatment for alcohol use disorders. In conclusion, while COVID-19 has dramatically reduced and limited services, the pandemic has propelled the importance of alcohol harm reduction and created new opportunities for implementation of harm reduction philosophy and approaches, including programs that incorporate the provision of alcohol as medicine as part of the substance use treatment continuum.

1 September 2002 in Addictive Behaviors
Verified
Journal Article
Closed access
Christos KouimtsidisChristos Kouimtsidis
Christos Kouimtsidis
MRMartina Reynolds
Martina Reynolds
ABAlexander Baldacchino
Alexander Baldacchino
EDEmma Dunmore
Emma Dunmore
SBStephen Byrne
Stephen Byrne
VCVanessa Crawford
Vanessa Crawford